EE05181B1 - Prasolo[4,3-d]primidiini derivaadid, neid sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja meetodid nende valmistamiseks - Google Patents
Prasolo[4,3-d]primidiini derivaadid, neid sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja meetodid nende valmistamiseksInfo
- Publication number
- EE05181B1 EE05181B1 EEP200200195A EEP200200195A EE05181B1 EE 05181 B1 EE05181 B1 EE 05181B1 EE P200200195 A EEP200200195 A EE P200200195A EE P200200195 A EEP200200195 A EE P200200195A EE 05181 B1 EE05181 B1 EE 05181B1
- Authority
- EE
- Estonia
- Prior art keywords
- rasolo
- preparation
- methods
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9924063.2A GB9924063D0 (en) | 1999-10-11 | 1999-10-11 | Pharmaceutically active compounds |
GB0018656A GB0018656D0 (en) | 2000-07-28 | 2000-07-28 | Pharmaceutically active compounds |
PCT/IB2000/001457 WO2001027113A2 (en) | 1999-10-11 | 2000-10-11 | PYRAZOLO `4,3-d! PYRIMIDINE DERIVATIVES |
Publications (2)
Publication Number | Publication Date |
---|---|
EE200200195A EE200200195A (et) | 2003-08-15 |
EE05181B1 true EE05181B1 (et) | 2009-06-15 |
Family
ID=26244757
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200195A EE05181B1 (et) | 1999-10-11 | 2000-10-11 | Prasolo[4,3-d]primidiini derivaadid, neid sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja meetodid nende valmistamiseks |
Country Status (49)
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7235625B2 (en) | 1999-06-29 | 2007-06-26 | Palatin Technologies, Inc. | Multiple agent therapy for sexual dysfunction |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
GB0000561D0 (en) * | 2000-01-11 | 2000-03-01 | Pfizer Ltd | Treatment of diabetic ulcers |
CA2406947A1 (en) * | 2000-04-19 | 2001-10-25 | Johns Hopkins University | Methods for prevention and treatment of gastrointestinal disorders |
US6271228B1 (en) * | 2000-04-28 | 2001-08-07 | Pfizer Inc. | Blood pressure stabilization during hemodialysis |
IL153226A0 (en) * | 2000-07-28 | 2003-07-06 | Pfizer | Crystalline therapeutic agent |
EP1176142A1 (en) * | 2000-07-28 | 2002-01-30 | Pfizer Inc. | Process for the preparation of pyrazoles |
US6420557B1 (en) | 2000-07-28 | 2002-07-16 | Pfizer Inc. | Crystalline therapeutic agent |
US6407259B1 (en) | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
GB0025782D0 (en) * | 2000-10-20 | 2000-12-06 | Pfizer Ltd | Use of inhibitors |
US6548508B2 (en) | 2000-10-20 | 2003-04-15 | Pfizer, Inc. | Use of PDE V inhibitors for improved fecundity in mammals |
FR2820319B3 (fr) * | 2001-02-08 | 2003-12-05 | Ellipse Pharmaceuticals | Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu |
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
KR20050004195A (ko) * | 2002-05-23 | 2005-01-12 | 화이자 인코포레이티드 | 신규 조합 제제 |
GB0214784D0 (en) * | 2002-06-26 | 2002-08-07 | Pfizer Ltd | Novel combination |
DE10229778A1 (de) * | 2002-07-03 | 2004-01-29 | Bayer Ag | Neue Verwendung von Imidazotriazinonen |
GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
US7323462B2 (en) | 2002-12-10 | 2008-01-29 | Pfizer Inc. | Morpholine dopamine agonists |
DE60332387D1 (de) | 2002-12-13 | 2010-06-10 | Warner Lambert Co | Alpha-2-delta-ligand zur behandlung vonsymptomen der unteren harnwege |
UA81453C2 (en) | 2003-02-27 | 2008-01-10 | Pyrazolopyridine derivates | |
GEP20084329B (en) | 2003-04-29 | 2008-03-25 | Pfizer Ltd | 5,7-diaminopyrazolo [4,3-d] pyrimidines useful in the treatment of hypertension |
JP2006527257A (ja) * | 2003-06-10 | 2006-11-30 | ファイザー・インク | 月経困難症の治療用のpde阻害剤及びバソプレッシン受容体アンタゴニストを含んでなる療法組合せ |
JP2006219373A (ja) * | 2003-06-13 | 2006-08-24 | Daiichi Asubio Pharma Co Ltd | Pde7阻害作用を有するピリジニルピラゾロピリミジノン誘導体 |
US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
DE10360835A1 (de) * | 2003-12-23 | 2005-07-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel |
US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
CA2562251C (en) | 2004-04-07 | 2009-04-28 | Pfizer Inc. | Pyrazolo'4,3-d pyrimidines |
US7618972B2 (en) | 2005-03-21 | 2009-11-17 | Pfizer Inc | Substituted triazole derivatives as oxytocin antagonists |
AU2006245416B2 (en) | 2005-05-12 | 2012-02-23 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
ES2645371T3 (es) | 2005-06-06 | 2017-12-05 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
EP2377530A3 (en) | 2005-10-21 | 2012-06-20 | Braincells, Inc. | Modulation of neurogenesis by PDE inhibition |
EP2314289A1 (en) | 2005-10-31 | 2011-04-27 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
AU2006327882A1 (en) * | 2005-12-20 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination for the treatment of LUTS comprising a PDE5 inhibitor and a muscarinic antagonist |
WO2007072156A1 (en) * | 2005-12-21 | 2007-06-28 | Pfizer Products Inc. | Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor |
UY30111A1 (es) * | 2006-02-03 | 2007-04-30 | Recordati Ireland Ltd | Sales de adicion de acido de n-(3-(4-(2-metoxifenil)-1-piperazinil)-propil)-7-oxo-5-trifluormetil-7h-tieno (3,2-b) piran-3-carboxamida |
US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
AU2007223036A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
WO2007134077A2 (en) * | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
CA2651813A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
US9255099B2 (en) | 2006-06-06 | 2016-02-09 | Intra-Cellular Therapies, Inc. | Pyrazolo[3,4-D]pyrimidine-4,6(5H,7H)-diones as phosphodiesterase 1 inhibitors |
US20080051413A1 (en) * | 2006-08-25 | 2008-02-28 | Kaohsiung Medical University | Nitrophenylpiperazine derivative of xanthine which relaxes tracheal airway and increases respiratory performance |
AU2007292848A1 (en) * | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
US20080081816A1 (en) * | 2006-10-03 | 2008-04-03 | Kaohsiung Medical University | Anti-inflammation activity of newly synthesized xanthine derivatives kmup-1 and kmup-3 |
JP5837278B2 (ja) | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規使用 |
CN101969774A (zh) | 2007-12-06 | 2011-02-09 | 细胞内治疗公司 | 有机化合物 |
MX2011005935A (es) | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
EP2358204B1 (en) | 2008-12-06 | 2015-08-05 | Intra-Cellular Therapies, Inc. | 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors. |
EA201170772A1 (ru) | 2008-12-06 | 2012-03-30 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
US8536159B2 (en) | 2008-12-06 | 2013-09-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
AU2009322903A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN102223799A (zh) | 2008-12-06 | 2011-10-19 | 细胞内治疗公司 | 有机化合物 |
EP2379076B1 (en) | 2008-12-23 | 2014-11-12 | The Trustees of Columbia University in the City of New York | Phosphodiesterase inhibitors and uses thereof |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
GB0903493D0 (en) | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
US9468637B2 (en) | 2009-05-13 | 2016-10-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2011153138A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
EP2575817A4 (en) | 2010-05-31 | 2014-01-08 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
JP5894148B2 (ja) | 2010-05-31 | 2016-03-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
JP6051210B2 (ja) | 2011-06-10 | 2016-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
US9402877B2 (en) | 2011-11-04 | 2016-08-02 | Xion Pharmaceuticals Corporation | Methods and compositions for oral administration of melanocortin receptor agonist compounds |
EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
WO2013109738A1 (en) | 2012-01-17 | 2013-07-25 | The Trustees Of Columbia University In The City Of New York | Novel phosphodiesterase inhibitors and uses thereof |
AR091507A1 (es) | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
US9801882B2 (en) | 2013-02-17 | 2017-10-31 | Intra-Cellular Therapies, Inc. | Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases |
CA2906640C (en) | 2013-03-15 | 2021-07-20 | Intra-Cellular Therapies, Inc. | Substituted imidazo-[1,2-a]pyrazolo[4.3-e]pyrimidin-4[5h]-one compounds and pharmaceutical compositions and use therof as pde1 inhibitors |
EP2968338B1 (en) | 2013-03-15 | 2019-01-09 | Intra-Cellular Therapies, Inc. | Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries |
WO2014205354A2 (en) | 2013-06-21 | 2014-12-24 | Takeda Pharmaceutical Company Limited | Free base crystals |
US10899756B2 (en) | 2013-07-17 | 2021-01-26 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
AR102315A1 (es) * | 2014-04-02 | 2017-02-22 | Bayer Cropscience Ag | Derivados de pirazolil-nicotin(tio)amida sustituidos y su uso como fungicidas |
DK3157926T3 (da) | 2014-06-20 | 2019-08-19 | Intra Cellular Therapies Inc | Organiske forbindelser |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
WO2016022893A1 (en) | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
MX2017003646A (es) | 2014-09-17 | 2017-07-13 | Intra Cellular Therapies Inc | Compuestos y metodos. |
JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規組成物および方法 |
WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
AR109595A1 (es) | 2016-09-09 | 2018-12-26 | Incyte Corp | Compuestos de pirazolopirimidina y usos de estos como inhibidores de hpk1 |
CN115819417A (zh) | 2016-09-09 | 2023-03-21 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物及其用于治疗癌症的用途 |
JP7134168B6 (ja) | 2016-09-12 | 2024-02-02 | イントラ-セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
EP3746081A4 (en) | 2018-01-31 | 2021-10-27 | Intra-Cellular Therapies, Inc. | INNOVATIVE USES |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
WO2019164846A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as hpk1 inhibitors for treating cancer |
WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
MA53726A (fr) | 2018-09-25 | 2022-05-11 | Incyte Corp | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
US11066394B2 (en) | 2019-08-06 | 2021-07-20 | Incyte Corporation | Solid forms of an HPK1 inhibitor |
CN113493459B (zh) * | 2020-04-07 | 2022-12-13 | 广州白云山医药集团股份有限公司白云山制药总厂 | Pde5抑制剂化合物及其制备方法和应用 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2089971A (en) | 1937-08-17 | Condensation products of | ||
DE425921C (de) * | 1923-08-11 | 1926-02-27 | Ernst Otto Baum | Pressluftzugmaschine fuer Bergwerke |
US4871843A (en) | 1983-10-18 | 1989-10-03 | Dropic-Societe Civile De Gestion De Droits De Propriete Industrielle | Cyclic benzenesulfonamides, process for their preparation and their use as active substance of pharmaceutical compositions |
FR2558263B1 (fr) * | 1984-01-12 | 1986-04-25 | Commissariat Energie Atomique | Accelerometre directif et son procede de fabrication par microlithographie |
US4663326A (en) | 1985-04-04 | 1987-05-05 | Warner-Lambert Company | Pyrazolo[4,3-d]pyrimidine-5,7-(4H,6H)dione or -5-thione-7-one analogs |
US4666908A (en) | 1985-04-05 | 1987-05-19 | Warner-Lambert Company | 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use |
US5075310A (en) | 1988-07-01 | 1991-12-24 | Smith Kline & French Laboratories, Ltd. | Pyrimidone derivatives as bronchodilators |
GB8817651D0 (en) | 1988-07-25 | 1988-09-01 | Smith Kline French Lab | Chemical compounds |
IL95975A (en) | 1989-10-24 | 1997-06-10 | Takeda Chemical Industries Ltd | N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
GB9114760D0 (en) | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
GB9119704D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic agents |
GB9121028D0 (en) | 1991-10-03 | 1991-11-13 | Pfizer Ltd | Therapeutic agents |
GB9126260D0 (en) | 1991-12-11 | 1992-02-12 | Pfizer Ltd | Therapeutic agents |
GB9202238D0 (en) | 1992-02-03 | 1992-03-18 | Wellcome Found | Compounds |
US5294612A (en) | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
US5734053A (en) | 1992-06-26 | 1998-03-31 | Pfizer Inc | Purinone antianginal agents |
GB9213623D0 (en) | 1992-06-26 | 1992-08-12 | Pfizer Ltd | Therapeutic agents |
GB9218322D0 (en) | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
GB9311920D0 (en) * | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9315017D0 (en) | 1993-07-20 | 1993-09-01 | Glaxo Lab Sa | Chemical compounds |
US5728705A (en) | 1993-10-04 | 1998-03-17 | The Trustees Of Columbia University In The City Of New York | Method of inducing vasorelaxation to treat pulmonary hypertension |
GB9423911D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
GB9423910D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
WO1996028448A1 (en) | 1995-03-10 | 1996-09-19 | Sanofi Winthrop, Inc. | 6-ARYL PYRAZOLO[3,4-d]PYRIMIDIN-4-ONES AND COMPOSITIONS AND METHODS OF USE THEREOF |
US5656629A (en) | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
US5952006A (en) | 1995-09-29 | 1999-09-14 | L.A.M. Pharmaceuticals, Llc | Drug preparations for treating impotency |
DE19540642A1 (de) | 1995-11-01 | 1997-05-07 | Stief Christian Georg Priv Doz | Verwendung von Inhibitoren der Phosphodiesterase bei der Behandlung von Prostataerkrankungen |
GB9612514D0 (en) | 1996-06-14 | 1996-08-14 | Pfizer Ltd | Novel process |
NZ338075A (en) * | 1997-04-25 | 2000-10-27 | Pfizer Ltd | Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PED5) for the treatment of sexual dysfunction |
ATE333279T1 (de) | 1997-05-19 | 2006-08-15 | Zonagen Inc | Kombinationstherapie zur modulation der humanen sexualreaktion |
IL132993A0 (en) | 1997-05-29 | 2001-03-19 | Mochida Pharm Co Ltd | Therapeutic agent for erection failure |
AU759825B2 (en) | 1997-12-16 | 2003-05-01 | Pfizer Products Inc. | Combination effective for the treatment of impotence |
TR200003039T2 (tr) * | 1998-04-20 | 2001-01-22 | Pfizer Inc. | Seksüel fonksiyon bozukluklarının tedavisi için pirazolopirimidinon cGMP PDE5 inhibitörleri |
AU4068599A (en) | 1998-05-20 | 1999-12-06 | Schering Corporation | Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction |
US6087368A (en) | 1998-06-08 | 2000-07-11 | Bristol-Myers Squibb Company | Quinazolinone inhibitors of cGMP phosphodiesterase |
CA2346350C (en) | 1998-10-05 | 2008-01-08 | Eisai Co., Ltd. | Intraoral quickly disintegrating tablets |
JP2000119198A (ja) | 1998-10-16 | 2000-04-25 | Eisai Co Ltd | 苦味等の隠蔽されたホスフォジエステラーゼ阻害剤含有経口製剤 |
CA2251255A1 (en) | 1998-10-20 | 2000-04-20 | Mcgill University | The use of dopaminergic agents in the management of sexual dysfunction |
IL132406A0 (en) | 1998-10-21 | 2001-03-19 | Pfizer Prod Inc | Treatment of bph with cgmp elevators |
CA2347950C (en) | 1998-10-23 | 2005-05-03 | Pfizer Inc. | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
GB9823101D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9828340D0 (en) | 1998-12-22 | 1999-02-17 | Novartis Ag | Organic compounds |
JP3199115B2 (ja) * | 1998-12-24 | 2001-08-13 | モトローラ株式会社 | デジタル・アナログ変換回路 |
DE19903087A1 (de) | 1999-01-27 | 2000-08-10 | Forssmann Wolf Georg | Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern |
CA2362918A1 (en) | 1999-03-08 | 2000-09-14 | Elizabeth Stoner | Methods and compositions for treating erectile dysfunction |
IL137429A0 (en) | 1999-07-28 | 2001-07-24 | Pfizer Prod Inc | Methods and compsitions for treating diseases and conditions of the eye |
AU5957600A (en) | 1999-07-30 | 2001-02-19 | Lakefield Minerals Ltd. | Pharmaceutical compositions for topical application to treat erectile dysfunction |
CA2378257A1 (en) | 1999-08-10 | 2001-02-15 | William E. Sponsel | Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight |
US6436944B1 (en) | 1999-09-30 | 2002-08-20 | Pfizer Inc. | Combination effective for the treatment of impotence |
TWI265925B (en) | 1999-10-11 | 2006-11-11 | Pfizer | Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them |
YU59100A (sh) | 1999-10-11 | 2003-10-31 | Pfizer Inc. | Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera |
US6420557B1 (en) * | 2000-07-28 | 2002-07-16 | Pfizer Inc. | Crystalline therapeutic agent |
US6407259B1 (en) * | 2000-07-28 | 2002-06-18 | Pfizer Inc. | Process for the preparation of pyrazoles |
-
2000
- 2000-09-14 TW TW089118861A patent/TWI265925B/zh not_active IP Right Cessation
- 2000-10-06 US US09/685,080 patent/US6677335B1/en not_active Expired - Fee Related
- 2000-10-09 MY MYPI20004712A patent/MY130319A/en unknown
- 2000-10-09 EG EG20001281A patent/EG24411A/xx active
- 2000-10-09 PH PH12000002783A patent/PH12000002783B1/en unknown
- 2000-10-10 GT GT200000171A patent/GT200000171A/es unknown
- 2000-10-10 PA PA20008504501A patent/PA8504501A1/es unknown
- 2000-10-10 TN TNTNSN00199A patent/TNSN00199A1/fr unknown
- 2000-10-11 GE GEAP20006408A patent/GEP20033142B/en unknown
- 2000-10-11 KR KR1020027004643A patent/KR100549152B1/ko not_active IP Right Cessation
- 2000-10-11 CZ CZ20021158A patent/CZ20021158A3/cs unknown
- 2000-10-11 SV SV2000000195A patent/SV2002000195A/es unknown
- 2000-10-11 CA CA002387357A patent/CA2387357C/en not_active Expired - Fee Related
- 2000-10-11 GE GEAP20005578A patent/GEP20033068B/en unknown
- 2000-10-11 CN CNB2005100625827A patent/CN100378100C/zh not_active Expired - Fee Related
- 2000-10-11 AT AT00966347T patent/ATE284404T1/de not_active IP Right Cessation
- 2000-10-11 DE DE60016615T patent/DE60016615T2/de not_active Expired - Lifetime
- 2000-10-11 CN CNB008151954A patent/CN1204138C/zh not_active Expired - Fee Related
- 2000-10-11 PE PE2000001090A patent/PE20010737A1/es not_active Application Discontinuation
- 2000-10-11 IL IL14902600A patent/IL149026A0/xx unknown
- 2000-10-11 OA OA1200200104A patent/OA12061A/en unknown
- 2000-10-11 SI SI200030593T patent/SI1220856T1/xx unknown
- 2000-10-11 DZ DZ003220A patent/DZ3220A1/fr active
- 2000-10-11 AP APAP/P/2002/002456A patent/AP1238A/en active
- 2000-10-11 EE EEP200200195A patent/EE05181B1/et not_active IP Right Cessation
- 2000-10-11 WO PCT/IB2000/001457 patent/WO2001027113A2/en active Application Filing
- 2000-10-11 EP EP00966347A patent/EP1220856B1/en not_active Expired - Lifetime
- 2000-10-11 EA EA200200337A patent/EA004982B1/ru not_active IP Right Cessation
- 2000-10-11 AU AU76784/00A patent/AU779065B2/en not_active Ceased
- 2000-10-11 SK SK460-2002A patent/SK4602002A3/sk unknown
- 2000-10-11 ES ES00966347T patent/ES2232502T3/es not_active Expired - Lifetime
- 2000-10-11 RS YUP-314/02A patent/RS50476B/sr unknown
- 2000-10-11 BR BR0014698-6A patent/BR0014698A/pt not_active Application Discontinuation
- 2000-10-11 NZ NZ518078A patent/NZ518078A/en unknown
- 2000-10-11 JP JP2001530331A patent/JP3834236B2/ja not_active Expired - Fee Related
- 2000-10-11 PT PT00966347T patent/PT1220856E/pt unknown
- 2000-10-11 TR TR2002/00989T patent/TR200200989T2/xx unknown
- 2000-10-11 DK DK00966347T patent/DK1220856T3/da active
- 2000-10-11 HU HU0203450A patent/HUP0203450A3/hu unknown
- 2000-10-11 PL PL00357536A patent/PL357536A1/xx not_active Application Discontinuation
- 2000-10-11 CN CNB2004100384099A patent/CN100383141C/zh not_active Expired - Fee Related
- 2000-10-11 CO CO00077467A patent/CO5251477A1/es not_active Application Discontinuation
-
2002
- 2002-03-21 IS IS6320A patent/IS2181B/is unknown
- 2002-03-21 CU CU20020060A patent/CU23198A3/es not_active IP Right Cessation
- 2002-03-28 IN IN385MU2002 patent/IN2002MU00385A/en unknown
- 2002-04-05 MA MA26586A patent/MA26825A1/fr unknown
- 2002-04-08 CR CR6617A patent/CR6617A/es not_active Application Discontinuation
- 2002-04-08 IL IL149026A patent/IL149026A/en not_active IP Right Cessation
- 2002-04-10 MX MXPA02003627 patent/MX228340B/es active IP Right Grant
- 2002-04-10 NO NO20021694A patent/NO322856B1/no not_active IP Right Cessation
- 2002-04-11 HR HR20020317A patent/HRP20020317B1/xx not_active IP Right Cessation
- 2002-05-09 BG BG106678A patent/BG106678A/bg unknown
-
2003
- 2003-04-10 HK HK03102607A patent/HK1050367A1/xx not_active IP Right Cessation
-
2004
- 2004-01-06 US US10/753,199 patent/US7176311B2/en not_active Expired - Fee Related
-
2005
- 2005-01-28 IN IN80MU2005 patent/IN2005MU00080A/en unknown
- 2005-03-11 HK HK05102106A patent/HK1069577A1/xx not_active IP Right Cessation
- 2005-11-18 HK HK05110418A patent/HK1078574A1/xx not_active IP Right Cessation
-
2006
- 2006-03-08 IN IN264MU2006 patent/IN2006MU00264A/en unknown
- 2006-08-11 US US11/463,931 patent/US20060293347A1/en not_active Abandoned
-
2007
- 2007-04-19 IN IN567MU2007 patent/IN2007MU00567A/en unknown
-
2008
- 2008-08-08 CR CR10191A patent/CR10191A/es not_active Application Discontinuation
-
2009
- 2009-05-20 US US12/469,311 patent/US20100035891A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE05181B1 (et) | Prasolo[4,3-d]primidiini derivaadid, neid sisaldavad farmatseutilised kompositsioonid, nende kasutamine ja meetodid nende valmistamiseks | |
EE200000168A (et) | Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid | |
HUP0400692A3 (en) | Substituted 7h-pyrrolo[2,3-d]pyrimidine derivatives, their use and pharmaceutical compositions containing them | |
EE200200138A (et) | Kinolüülpropüülpiperidiini derivaadid, nende valmistamine ja neid sisaldavad kompositsioonid | |
EE04193B1 (et) | Triasolo[4,5-d]pürimidiini ühendid, neid sisaldavad ravimkoostised ja nende valmistamise meetodid | |
EE200100484A (et) | Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid,ja nende valmistamise meetodid | |
HUP0301722A3 (en) | Pyrimidine derivatives, pharmaceutical compositions containing them and their use | |
EE04673B1 (et) | Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid | |
EE04679B1 (et) | Tuumorivastase toimega kamptotetsiini derivaadid,meetod nende valmistamiseks ja neid hendeid sisaldavad farmatseutilised kompositsioonid | |
EE200200065A (et) | 3-aminopürasooli derivaadid, nende valmistamine ja kasutamine vähivastaste toimeainetena ning neid sisaldav farmatseutiline kompositsioon | |
IL148876A0 (en) | Sulfonamide derivatives, their preparation and pharmaceutical compositions containing them | |
EE04399B1 (et) | Spiroasabitsüklilised heterotsüklilised ühendid, nende valmistamise protsess, neid sisaldavad ravimkoostised ja nende kasutamine ravis | |
EE200100252A (et) | Pürimidiinderivaadid, nende valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja sellevalmistamismeetod, kombinatsioon ning saadus | |
HUP0203548A3 (en) | New spirooxindole derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0202795A3 (en) | Pyrimidine and pyrazine derivatives, pharmaceutical compositions containing them and their use | |
HUP0203294A3 (en) | Benzodiazepine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
EE04275B1 (et) | Kinoliini derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutilised kompositsioonid | |
HUP0300618A3 (en) | Adamantana derivatives, process for their preparation, their use and pharmaceutical compositions containing them | |
EE04853B1 (et) | Adenosiini derivaadid ja neid sisaldavad farmatseutilised kompositsioonid kasutamiseks meditsiinis | |
HUP0102102A3 (en) | Pyrazoline derivatives, their preparation, pharmaceutical compositions containing them and their use | |
SI0918059T1 (en) | Substituted imidazoline derivatives, their preparation, their use, and pharmaceutical compositions containing them | |
EE04276B1 (et) | Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid | |
HUP0002902A3 (en) | 3-substituted 3,4 dyhydro-thieno[2,3-d]pyrimidine derivatives and their use for the preparation of pharmaceutical compositions | |
HUP0203385A3 (en) | Pyrimidine derivatives, process for their preparation, pharmaceutical compositions containing them and their use | |
HUP0002272A3 (en) | Aroyl-piperazine derivatives, their preparation pharmaceutical compositions containing them and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB4A | Valid patent at the end of a year |
Effective date: 20101231 |
|
MM4A | Lapsed by not paying the annual fees |
Effective date: 20101011 |